Existing HIV Therapies Also Block Virus Associated with Prostate Cancer and Chronic Fatigue Syndrome

Merck & Co.’s anti-HIV drug, Isentress, is effective against a recently discovered retrovirus called XMRV (xenotropic murine leukemia-related retrovirus) that has been linked with prostate cancer and chronic fatigue symdrome (CFS), report researchers from the University of Utah and Emory University/Veterans Affairs Medical Center. They suggest that if XMRV can be shown to have a causative role in these two diseases, they may be treatable with an existing medication.

More @ GEN